T-Cell Redirecting Strategies in Large B-Cell Lymphoma and Follicular Lymphoma
{{output}}
The advent of chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory large B-cell lymphoma (LBCL). After achieving regulatory approval in third line (3L+), randomized trials confirmed superiority over s... ...
